CANDIDATEZ AU PROGRAMME D'ACCÉLÉRATION SANTÉ

Fermer définitivement
Fermer le menu

 

 

 

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

 

 

 

  • The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today.
  • The DSMB recommended that the study continue as planned.
  • MaaT033 continues to demonstrate a favorable safety profile and tolerability.

 

 

Read the press release

Plus d'infos